Survivin Antibody
Code | Size | Price |
---|
PSI-2233-0.02mg | 0.02mg | £150.00 |
Quantity:
PSI-2233-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Images
Documents
Further Information
Additional Names:
Survivin Antibody: API4, EPR-1, API4, IAP4, Baculoviral IAP repeat-containing protein 5, Apoptosis inhibitor 4
Application Note:
WB: 1-5μg/mL; ICC: 5 μg/mL; IF: 20 μg/mL; IHC: 5 μg/mL.
Antibody validated: Western Blot in human samples; Immunocytochemistry in human samples; Immunofluorescence and Immunohistochemistry in mouse samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunocytochemistry in human samples; Immunofluorescence and Immunohistochemistry in mouse samples. All other applications and species not yet tested.
Background:
Survivin Antibody: Apoptosis, or programmed cell death, is related to many diseases, such as cancer. Apoptosis is triggered by a variety of stimuli including members in the TNF family and prevented by the inhibitor of apoptosis (IAP) proteins. IAP proteins form a conserved gene family that binds to and inhibits cell death proteases. A novel IAP protein was recently identified and designated survivin, apoptosis inhibitor 4 (API4), and TIAP. Survivin/TIAP interacted with the processed form of caspase-3 and inhibited its proteolytic activity. Survivin/TIAP is predominantly expressed in tissues of embryos, transformed cell lines, and many human cancers and lymphomas.
Background References:
- Ambrosini et al. Nat Med 1997;3:917-21.
- Ambrosini et al. Nat Med 1997;3:917-21.
- Kobayashi et al. Proc Natl Acad Sci USA 1999;96:1457-62 (WD0600).
Buffer:
Survivin Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Pig: (82%), Bovine: (82%), Rat: (58%)
Immunogen:
Anti-Survivin antibody (2233) was raised against a peptide corresponding to 12 amino acids near the amino terminus of human Survivin.
The immunogen is located within the first 50 amino acids of Survivin.
The immunogen is located within the first 50 amino acids of Survivin.
ISOFORMS:
Human Survivin has 7 isoforms, including isoform 1 (142aa, 16kD), isoform 2 (165aa, 19kD), isoform 3 (137aa, 16kD), isoform 4 (120aa, 14kD), isoform 5 (117aa, 14kD), isoform 6 (78aa, 9kD) and isoform 7 (74aa, 8.5kD). Mouse Survivin has 3 isoforms, including isoform 1 (140aa, 16kD), isoform 2 (121aa, 14kD) and isoform 3 (40aa, 4.7kD). Rat Survivin has one isoform (142aa, 17kD). 2233 can detect human and mouse.
NCBI Gene ID #:
332
NCBI Official Name:
baculoviral IAP repeat-containing 5
NCBI Official Symbol:
BIRC5
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 17kD
Observed: 17 kD
Observed: 17 kD
Protein Accession #:
NP_001159
Protein GI Number:
59859878
Purification:
Survivin Antibody is affinity chromatography purified via peptide column.
Research Area:
Apoptosis,Cancer
Swissprot #:
O15392
User NOte:
Optimal dilutions for each application to be determined by the researcher.
VALIDATION:
Independent Antibody Validation in Cell lines (Figure 2) shows similar Survivin expression profile in human cell lines detected by two independent anti-Survivin antibodies that recognize different epitopes, 2233 against N-terminus domain and 2235 against C-terminus domain. Survivin proteins are detected in the most tested cell lines at different expression levels by the two independent antibodies.
Related Products
Product Name | Product Code | Supplier | Survivin Peptide | PSI-2233P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|